Publish date: July 8, 2011
Note: This is an archived resource. It is provided here for general reference, but users are advised to refer to other sources to confirm information. See full site Disclaimer.
David Spach, MD
22 slides covering the data behind the recent FDA approval of the new NNRTI, Rilpivirine (Edurant), and in particular, how it compares to Efavirenz.
Topic(s): Step 5: Effective Drug Treatment of HIV, Antiretroviral Therapy
Resource type: Slide Sets